Candida albicans colonization and ASCA in familial crohn's disease

American Journal of Gastroenterology

Volumn 104, Issue 7, 2009, Pages 1745-1753

  Standaert Vitse, Annie ^a,b   Sendid, Boualem ^a,c   Joossens, Marie ^d   François, Nadine ^c   Vandewalle El Khoury, Peggy ^a   Branche, Julien ^a,c   Van Kruiningen, Herbert ^e   Jouault, Thierry ^a   Rutgeerts, Paul ^d   Gower Rousseau, Corinne ^c   Libersa, Christian ^f   Neut, Christel ^b   Broly, Franck ^g   Chamaillard, Mathias ^a,c   Vermeire, Séverine ^d   Poulain, Daniel ^a,c   Colombel, Jean Frédéric ^a,c  

^a INSERM   (France)

^b UNIV LILLE   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e UNIVERSITY OF CONNECTICUT   (United States)

^f University of Lille   (France)

^g France Institut Pasteur de Lille   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; CANDIDA ALBICANS MANNAN ANTIBODY; FUNGUS ANTIBODY; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MANNAN; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; SACCHAROMYCES CEREVISIAE ANTIBODY; STEROID; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBIOTIC THERAPY; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA TROPICALIS; CIGARETTE SMOKING; COLON CROHN DISEASE; CONTROLLED STUDY; CROHN DISEASE; DIGESTIVE SYSTEM; DISEASE DURATION; DISEASE PREDISPOSITION; FAMILIAL DISEASE; FAMILY STUDY; FECES ANALYSIS; FEMALE; FUNGUS ISOLATION; HUMAN; ILEUM DISEASE; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MOUTH; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SACCHAROMYCES CEREVISIAE; STEROID THERAPY; YEAST;

EID: 67650429655     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.225     Document Type: Article

References (73)

1. Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest 2007;17:514-2.
2. Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis . Nat Clin Pract Gastroenterol Hepatol 2006 ; 3 : 390-407.
3. Bossuyt X. Serologic markers in inflammatory bowel disease . Clin Chem 2006;52:171-81.
4. Quinton JF, Sendid B, Reumaux D et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoanti-bodies in inflammatory bowel disease: prevalence and diagnostic role . Gut 1998;42:788-91.
5. Ruemmele FM, Targan SR Levy G et al. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease . Gastroenterology 1998 ; 115 : 822-9.
6. Peeters M, Joossens S, Vermeire S et al. Diagnostic value of anti-S accharo-myces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease . Am J Gastroenterol 2001 ; 96 : 730-4.
7. Vermeire S, Peeters M, Vlietinck R et al. Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families . Inflamm Bowel Dis 2001;7:8-5.
8. Muller S, Styner M, Seibold-Schmid B et al. Anti-Saccharomyces cerevisiae antibody titers are stable over time in Crohn's patients and are not inducible in murine models of colitis . World J Gastroenterol 2005 ; 11 : 6988-94.
9. Teml A, Kratzer V, Schneider B et al. Anti-Saccharomyces cerevisiae antibodies: a stable marker for Crohn's disease during steroid and 5-aminosali-cylic acid treatment . Am J Gastroenterol 2003 ; 98 : 2226-31.
10. Israeli E, Grotto I, Gilburd B et al. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease . Gut 2005 ; 54 : 1232-6.
11. Poulain D, Sendid B, Fajardy I et al. Mother to child transmission of anti-S. cerevisiae mannan antibodies (ASCA) in non-IBD families . Gut 2000;47:870- 1.
12. Sendid B, Quinton JF, Charrier G et al. Anti-Saccharomyces cerevisiae mannan antibodies in familial Crohn's disease . Am J Gastroenterol 1998 ; 93 : 1306-10.
13. Sutton CL, Yang H, Li Z et al. Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn's disease . Gut 2000 ; 46 : 58-63.
14. Annese V, Andreoli A, Andriulli A et al. Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in Crohn's disease and ulcerative colitis: a GISC study . Am J Gastroenterol 2001 ; 96 : 2407-12.
15. Seibold F, Stich O, Hufnagl R et al. Anti-Saccharomyces cerevisiae antibodies in inflammatory bowel disease: a family study . Scand J Gastroenterol 2001;36:196-201.
16. Standaert-Vitse A Jouault T, Vandewalle P et al. Candida albicans is an immunogen for anti-Saccharomyces cerevisiae antibody markers of Crohn's disease . Gastroenterology 2006 ; 130 : 1764-75.
17. Jawhara S, Thuru X, Standaert-Vitse A et al. Colonization of mice by Candida albicans is promoted by chemically induced colitis and augments inflammatory responses through galectin-3 . J Infect Dis 2008;197:972-80.
18. Schafer T, Muller S, Flogerzi B et al. Anti-Saccharomyces cerevisiae mannan antibodies (ASCA) of Crohn's patients crossreact with mannan from other yeast strains, and murine ASCA IgM can be experimentally induced with Candida albicans . Inflamm Bowel Dis 2007 ; 13 : 1339-46.
19. Zelante T, De Luca A, Bonifazi P et al. IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance . Eur J Immunol 2007 ; 37 : 2695-706.
20. Molinie F, Gower-Rousseau C, Yzet T et al. Opposite evolution in incidence of Crohn's disease and ulcerative colitis in Northern France (1988 -1999) . Gut 2004;53:843-8.
21. Van Kruiningen HJ, Joossens M, Vermeire S et al. Environmental factors in familial Crohn's disease in Belgium . Inflamm Bowel Dis 2005;11:360-5.
22. Kozel TR, MacGill RS, Percival A et al. Biological activities of naturally occurring antibodies reactive with Candida albicans mannan . Infect Immun 2004;72:209-18.
23. Satsangi J, Silverberg MS, Vermeire S et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications . Gut 2006;55:749-53.
24. Sendid B, Colombel JF, Jacquinot PM et al. Specifc antibody response to oligomannosidic epitopes in Crohn's disease . Clin Diagn Lab Immunol 996;3:219-26.
25. Quindos G, San Millan R, Robert Ret al. Evaluation ofbichro-latex albicans, a new method for rapid identification of Candida albicans. J Clin Microbiol 1997 ; 35 : 1263-5.
26. Sartor RB. Microbial influences in inflammatory bowel diseases . Gastroenterology 2008; 134:577-94.
27. Darfeuille-Michaud A, Boudeau J, Bulois P et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease . Gastroenterology 2004;27:412-21.
28. Kotlowski R, Bernstein CN, Sepehri S et al. High prevalence of Escherichia coli belonging to the B2+D phylogenetic group in inflammatory bowel disease. Gut 2007;56:669-75.
29. Martin HM, Campbell BJ, Hart CA et al. Enhanced Escherichia coli adherence and invasion in Crohn's disease and colon cancer . Gastroenterology 2004;127:80-93.
30. Mylonaki M, Rayment NB, Rampton DS et al. Molecular characterization of rectal mucosa-associated bacterial flora in inflammatory bowel disease . Infamm Bowel Dis 2005;11:48-7.
31. Swidsinski A, LadhofA, Pernthaler A et al. Mucosal fora in inflammatory bowel disease. Gastroenterology 2002;122:44-54.
32. Odds FC (ed). Candida and Candidosis , 2nd edn. Bailliere Tindall: Philadelphia, PA , 1988 .
33. Lockhart SR, Joly S, Vargas K et al. Natural defenses against Candida colonization breakdown in the oral cavities of the elderly . J Dent Res 1999;78:857-68.
34. Pirotta MV, Garland SM. Genital Candida species detected in samples from women in Melbourne, Australia, before and after treatment with antibiotics . J Clin Microbiol 2006 ; 44 : 3213-7.
35. Qi QG, Hu T, Zhou XD. Frequency, species and molecular characterization of oral Candida in hosts of different age in China . J Oral Pathol Med 2005;34:352-6.
36. Xu J, Boyd CM, Livingston E et al. Species and genotypic diversities and similarities of pathogenic yeasts colonizing women . J Clin Microbiol 1999 ; 37 : 3835-43.
37. Soysa NS, Ellepola AN. The impact of cigarette/tobacco smoking on oral candidosis: an overview . Oral Dis 2005 ; 11 : 268-73.
38. Tuvlin JA, Raza S, Bracamonte S et al. Smoking and inflammatory bowel disease: trends in familial and sporadic cohorts . Inflamm Bowel Dis 2007;13:573-9.
39. Blair Y, Bagg J, MacFarlane TW et al. Microbiological assessment of denture hygiene among patients in longstay and daycare community places . Community Dent Oral Epidemiol 1995 ; 23 : 100-3.
40. Grimoud AM, Marty N Bocquet H et al. Colonization of the oral cavity by Candida species: risk factors in long-term geriatric care . J Oral Sci 2003;45:51-5.
41. Kulak-Ozkan Y, Kazazoglu E, Arikan A. Oral hygiene habits, denture cleanliness, presence of yeasts and stomatitis in elderly people . J Oral Rehabil 2002;29:300-4.
42. Samaranayake LP. Nutritional factors and oral candidosis. J Oral Pathol 1986;15:61-5.
43. Netea MG, Van Der Graaf CA, Vonk AG et al. The role of toll-like receptor (TLR) 2 and TLR4 in the host defense against disseminated candidiasis . J Infect Dis 2002 ; 185 : 1483-9.
44. Brown GD, Gordon S. Immune recognition. A new receptor for beta-glucans. Nature 2001;413:36-7.
45. Cambi A, Gijzen K, de Vries JM et al. The C-type lectin DC-SIGN (CD209) is an antigen-uptake receptor for Candida albicans on dendritic cells . Eur J Immunol 2003;33:532-8.
46. Fradin C, Poulain D, Jouault T. Beta-1,2-linked oligomannosides from Candida albicans bind to a 32-kilodalton macrophage membrane protein homologous to the mammalian lectin galectin-3 . Infect Immun 2000 ; 68 : 4391-8.
47. Lillegard JB, Sim RB, Thorkildson P et al. Recognition of Candida albicans by mannan-binding lectin in vitro and in vivo . J Infect Dis 2006 ; 193 : 1589-97.
48. Poulain D, Jouault T. Candida albicans cell wall glycans, host receptors and responses: elements for a decisive crosstalk . Curr Opin Microbiol 2004 ; 7 : 342-9.
49. Gantner BN, Simmons RM, Canavera SJ et al. Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2 . J Exp Med 2003 ; 197 : 1107-17.
50. Gross O, Gewies A, Finger K et al. Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity . Nature 2006 ; 442 : 651-6.
51. Jouault T, El Abed-El Behi M, Martinez-Esparza M et al. Specifc recognition of Candida albicans by macrophages requires galectin-3 to discriminate Saccharomyces cerevisiae and needs association with TLR2 for signaling . J Immunol 2006 ; 177 : 4679-87.
52. Netea MG, Gow NA, Munro CA et al. Immune sensing of Candida albicans requires cooperative recognition of mannans and glucans by lectin and Toll-like receptors . J Clin Invest 2006 ; 116 : 1642-50.
53. Van der Graaf CA, Netea MG, Morre SA et al. Toll-like receptor 4 Asp299Gly/Thr399Ile polymorphisms are a risk factor for Candida bloodstream infection . Eur Cytokine Netw 2006 ; 17 : 29-34.
54. De Jager PL, Franchimont D, Waliszewska A et al. The role of the Toll receptor pathway in susceptibility to inflammatory bowel diseases . Genes Immun 2007;8:387-97.
55. Franchimont D, Vermeire S, El Housni H et al. Defcient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut 2004;53:987-92.
56. Netea MG, Ferwerda G, de Jong DJ et al. Nucleotide-binding oligomeri-zation domain-2 modulates specific TLR pathways for the induction of cytokine release . J Immunol 2005 ; 174 : 6518-23.
57. van der Graaf CA, Netea MG, Franke B et al. Nucleotide oligomerization domain 2 (Nod2) is not involved in the pattern recognition of Candida albicans. Clin Vaccine Immunol 2006 ; 13 : 423-5.
58. McGovern D, Powrie F. The IL23 axis plays a key role in the pathogenesis of IBD . Gut 2007 ; 56 : 1333-6.
59. Netea MG, Brown GD, Kullberg BJ et al. An integrated model of the recognition of Candida albicans by the innate immune system . Nat Rev Microbiol 2008;6:67-78.
60. Palm NW, Medzhitov R. Antifungal defense turns 17. Nat Immunol 2007;8:549-51.
61. Torosantucci A, Bromuro C, Chiani P et al. A novel glyco-conjugate vaccine against fungal pathogens. J Exp Med 2005;202:597-606.
62. Han Y, Kozel TR, Zhang MX et al. Complement is essential for protection by an IgM and an IgG3 monoclonal antibody against experimental, hematogenously disseminated candidiasis . J Immunol 2001 ; 167 : 1550-7.
63. Han Y, Morrison RP, Cutler JE. A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection . Infect Immun 1998 ; 66 : 5771-6.
64. Greenfeld RA, Troutt DL, Rickard RC et al. Comparison of antibody, antigen, and metabolite assays in rat models of systemic and gastrointestinal candidiasis . J Clin Microbiol 1988 ; 26 : 409- 17.
65. Seibold F, Boldt AB, Seibold-Schmid B et al. Association of defciency for mannan-binding lectin with anti-mannan antibodies in Crohn's disease: a family study. Infamm Bowel Dis 2007 ; 13 : 1077-82.
66. van Till JW, Modderman PW, de Boer M et al. Mannose-binding lectin deficiency facilitates abdominal Candida infections in patients with secondary peritonitis . Clin Vaccine Immunol 2008 ; 15 : 65-70.
67. Jurevic RJ, Bai M, Chadwick RB et al. Single-nucleotide polymorphisms (SNPs) in human beta-defensin 1: high-throughput SNP assays and association with Candida carriage in type I diabetics and nondiabetic controls . J Clin Microbiol 2003 ; 41 : 90-6.
68. Lakatos PL, Altorjay I, Mandi Y et al. Interaction between seroreactivity to microbial antigens and genetics in Crohn's disease: is there a role for defensins? Tissue Antigens 2008;7:552-9.
69. D'Inca R, Annese V di Leo V et al. Increased intestinal permeability and NOD2 variants in familial and sporadic Crohn's disease . Aliment Pharmacol Ther 2006 ; 23 : 1455-61.
70. Rahimi R, Nikfar S, Rezaie A et al. A meta-analysis of broad-spectrum antibiotic therapy in patients with active Crohn's disease . Clin Ther 2006 ; 28 : 1983-8.
71. Rutgeerts P, Hiele M, Geboes K et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection . Gastroenterology 1995 ; 108 : 1617-21.
72. Rutgeerts P, Van Assche G, Vermeire S et al. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2005;128:856-61.
73. Selby W, Pavli P, Crotty B et al. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease . Gastroenterology 2007 ; 132 : 2313-9.